港股異動丨H&H國際控股(1112.HK)漲近2% 連續10個交易日上漲
格隆匯5月14日丨H&H國際控股(1112.HK)漲近2%,有望實現10連漲,暫報36.9港元,總市值237.7億港元。H&H國際控股一季度的業績成為股價的助推器,其今年首季收益24.24億元人民幣,按年增加11.5%。富瑞發表研究報告指,H&H國際控股今年首季業績勝預期,主要由於山羊IMF快速增長,加上免疫產品需求強勁。不過,該行指其代購需求減少,加上第二季處於高基數,會造成公司增長的阻礙,但預期其新產品及中國的直接銷售能帶動銷售增長。富瑞維持其買入投資評級,目標價40港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.